These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29748210)

  • 1. Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
    Marzi L; Agama K; Murai J; Difilippantonio S; James A; Peer CJ; Figg WD; Beck D; Elsayed MSA; Cushman M; Pommier Y
    Mol Cancer Ther; 2018 Aug; 17(8):1694-1704. PubMed ID: 29748210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
    Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
    Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
    Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
    Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
    Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
    Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
    Pommier Y; Cushman M
    Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Topoisomerase I in the Era of Precision Medicine.
    Thomas A; Pommier Y
    Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
    Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular determinants of response to topoisomerase I inhibitors].
    Pourquier P; Lansiaux A
    Bull Cancer; 2011 Nov; 98(11):1287-98. PubMed ID: 22049384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
    Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
    Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
    Liao Z; Robey RW; Guirouilh-Barbat J; To KK; Polgar O; Bates SE; Pommier Y
    Mol Pharmacol; 2008 Feb; 73(2):490-7. PubMed ID: 17984197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
    Teicher BA
    Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
    Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
    Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
    Sooryakumar D; Dexheimer TS; Teicher BA; Pommier Y
    Mol Cancer Ther; 2011 Aug; 10(8):1490-9. PubMed ID: 21636699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.